Skip to main content

Ciitizen raises $17 million to give cancer patients better control over their health records

Ciitizen, the company founded by the creators of Gliimpse (an Apple acquisition that’s been incorporated into the company’s HealthKit) which is developing tools to help patients organize and share their medical records, has raised $17 million in new funding. Ciitizen, like Gliimpse before it, is an attempt to break down the barriers that keep patients […]

Ciitizen, the company founded by the creators of Gliimpse (an Apple acquisition that’s been incorporated into the company’s HealthKit) which is developing tools to help patients organize and share their medical records, has raised $17 million in new funding.

Ciitizen, like Gliimpse before it, is an attempt to break down the barriers that keep patients from being able to record, store, and share their healthcare information with whomever they want in their quest for treatment.

The digitization of health records — a featured element of President Barack Obama’s overhaul of the healthcare system back in 2009 — remains an obstacle to quality care and proper treatment nearly a decade later. Hospitals spend millions and the US healthcare system spends billions on Electronic Health Records annually. All with very little too show for the expense.

Those kinds of challenges are what attracted investors in the Andreessen Horowitz -led round. New investors Section 32, formed by the former head of Google Ventures, Bill Maris; and Verily, one of the healthcare subsidiaries that spun out of Google X and is a part of Google’s parent company, Alphabet.

“Ciitizen uniquely understands the challenges cancer patients face – including the intense friction patients experience when managing their medical records in our current healthcare system,” said Vijay Pande, a general partner in Andreessen Horowitz’s Bio fund, in a statement. “Using their deep insights, the Ciitizen team have developed sophisticated technology and tools that remove this friction, putting the power back in the patients’ hands and literally saving lives.”

Pande may be a little biased since Andreessen Horowitz also led the company’s seed funding last July, in what was, at the time, one of the earlier investments from the Bio fund’s latest $450 million second investment vehicle.

Andreessen Horowitz has a new, $450 million bio fund

“The continued support from Andreessen Horowitz reaffirms the rapid progress we have already made and further validates our potential to significantly impact healthcare globally. Adding Section 32 and Verily to our effort further enhances our ability to transform the way patients engage with their health data,” said Anil Sethi, CEO and Founder of Ciitizen, in a statement.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.